GTBP
GT Biopharma, Inc.
Healthcare — Biotechnology
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
Price History
Fundamentals
| Market Cap | $17.82M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.05 |
| EPS (TTM) | $-6.46 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -921.55% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $3.00 |
| Analysts | 1 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 62.1 |
| Beta | 0.86 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.09 |
| 52-Week Low | $0.26 |
| 50-Day Avg | $0.41 |
| 200-Day Avg | $0.57 |
| Avg Volume | $1.46M |
| Volume | $1.25M |
Performance Analysis
NEUTRALGTBP presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:12 UTC
Back to Screener Export Report